RxDoctor Payments Data

Lindsey Cope

Family · Nashville, TNNPI 1700385473

Payments from drug & device makers

$3,120in general payments, 2019–2025

Across 199 payments — averaging $15.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$821
  • AbbVie$440
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$402
  • Pfizer$164
  • Boehringer Ingelheim$151
  • Xeris Pharmaceuticals, Inc.$123
  • plus $1K from 22 others

What the payments were for

  • Food & beverage$3,120100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,120 in reported general payments places this provider in the 80th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$49,780
Medicare patients
232
Services billed
3,404

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban76$74,939
MounjaroTirzepatide49$62,926
OzempicSemaglutide52$58,913
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$32,612
Tresiba Flextouch U-200Insulin Degludec25$28,551
XareltoRivaroxaban27$21,347
TradjentaLinagliptin14$18,384
JardianceEmpagliflozin29$17,220
JanuviaSitagliptin Phosphate13$15,792
RybelsusSemaglutide13$11,898
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$10,558
Breo ElliptaFluticasone/Vilanterol16$10,293
FarxigaDapagliflozin Propanediol16$9,845
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen168$3,911
ButransBuprenorphine11$3,677

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$164$74,93976 claims
Novo NordiskOzempic, Rybelsus$821$70,81165 claims
Lilly USA, LLCMounjaro$67$62,92649 claims
GSKTrelegy Ellipta, Breo Ellipta$29$42,90544 claims
Boehringer IngelheimTradjenta, Jardiance$151$35,60443 claims
AstraZenecaBreztri Aerosphere, Farxiga$89$20,40333 claims
AbbVieSynthroid$440$80515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,706 family providers in Tennessee.

Other family in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →